20 Mar 2023 Bionest FDA Finalizes Guidance on Multiple Endpoints in Clinical Trials Assessing multiple endpoints in clinical trial results can prove challenging, prompting the FDA to provide new guidance for drug sponsors.
13 Mar 2023 Bionest Alzheimer’s Disease Update Part 2: The Importance of Amyloid and Its Clearance in AD Could cellular waste management be key in treating Alzheimer's Disease? We explore this emerging field of research and potential for new AD drugs.
21 Feb 2023 Bionest Alzheimer’s Disease Update Part 1: Lecanemab Provides New Support for the Amyloid Hypothesis What will the recent accelerated approval of anti-amyloid lecanemab mean for Alzheimers patients, and will it overcome stringent CMS reimbursement policies?
19 Dec 2022 Bionest COVID Vaccines Transition from Government Supply to Private Marketplace What will be the impact of moving COVID vaccines to the private marketplace? We examine both the challenges and new opportunities for the companies.
5 Dec 2022 Bionest Medicare Drug Price Negotiations: Potential Impacts What impact will the Inflation Reduction Act have on pharma & biotech companies and what should they consider in their pipeline development plans?
21 Nov 2022 Bionest Competitors Collaborate to Understand Shared DMD Adverse Event Adverse responses to experimental gene therapies for Duchenne muscular dystrophy leads to unique collaboration between pharma competitors.
7 Nov 2022 Bionest Down to the Wire: The Race Between Amgen and Mirati for KRAS-Inhibitor Approvals Who is ahead in the race for KRAS-inhibitor approval? We explore the latest drug development updates for sotorasib and adagrasib.
10 Oct 2022 Bionest Are the Blues Ending for Bluebird? Gene therapy developer bluebird bio may be turning a corner, with recent FDA approvals for two of its rare disease therapeutics.
25 Apr 2022 Bionest Biosimilars on the Rise, Spurring Company Integration and Consolidation From one to 34: Biosimilars are on the rise. How will it affect the pharmaceutical market for companies and consumers?
28 Mar 2022 Bionest ASH 2021 Update: Part 2 A look at new hematology therapy developments for hemophilia, beta thalassemia and sickle cell disease presented at ASH 2021.